EN DE
STOCK COMPARISON

Cereno Scientific AB Series B vs Merck & Company: Fair Value & Quality

Both stocks run through our valuation models. Here is how Cereno Scientific AB Series B (CRNO-B) and Merck & Company (MRK) compare, as of Sep 5, 2026.

As of Sep 5, 2026, Fair Value Calculator sees Merck & Company as the less overvalued of the two: Cereno Scientific AB Series B trades at SEK 4.36 versus a fair value of SEK 0.46 (-89%), while Merck & Company trades at $150 versus $125 (-17%).
Cereno Scientific AB Series B
CRNO-B.ST · SEK · Health Care
-89%
upside to fair value
overvalued
PriceSEK 4.36
Fair ValueSEK 0.46
Quality31/100
Merck & Company
MRK · USD · Health Care
-17%
upside to fair value
overvalued
Price$150
Fair Value$125
Quality70/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Cereno Scientific AB Series BMerck & Company
Valuation
P/E (TTM)43.5×
2.26×P/S (TTM)4.64×
0.60×P/B5.80×
EV/EBITDA11.4×
PEG6.10×
−89.5%Fair value upside−16.6%
Dividend yield2.2%
Dividend per share$3.28
Profitability
-56%Operating margin39%
EBIT margin trend (5Y)2.70×
-61%Return on equity19%
-12%Return on assets13%
Growth
137%Revenue growth (YoY)5%
Avg. growth/yr (3Y)3.1%
Avg. growth/yr (5Y)9.4%
Value creation/yr+16.0%
Balance & size
Interest coverage (EBIT/interest)17.3×
0.50×Debt / equity0.89×
$151MMarket cap$305B
Growth qualityhealthy

Even match: 3 to 3 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Cereno Scientific AB Series Bof which business quality 31 · market factors 23 Merck & Companyof which business quality 68 · market factors 89
ProfitabilityMargins and returns on capital today
5
74
Quality GrowthAre margins and returns improving?
25
36
CashflowEarnings quality: real cash, not paper profit
30
65
Fin. StrengthBalance sheet, leverage, solvency risk
83
68
InvestmentDisciplined investing over empire-building
31
71
Low VolatilityCalm price path (market factor)
53
83
MomentumPrice trend over the last 3–12 months (market factor)
15
86
52W MomentumDistance to the 52-week high (market factor)
1
100
Net IssuanceBuybacks instead of dilution
0
91

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyCereno Scientific AB Series BPrice SEK 4.36Merck & CompanyPrice $150
DCF Modelsn/a-22%below the price$117
Earnings-Basedn/a-58%below the price$62.77
Dividend Discountn/a-60%below the price$60.35
Multiplesn/a-19%below the price$122
Asset-Based-88%below the priceSEK 0.54-91%below the price$14.27
Growth DCFn/a-51%below the price$74.00
Economic Profitn/a-44%below the price$83.85
Growth Earningsn/a-8%close to the price$138
Minimum-88%below the priceSEK 0.54-91%below the price$14.27
Maximum-88%below the priceSEK 0.54-8%close to the price$138
Median-88%below the priceSEK 0.54-47%below the price$78.93
Geometric mean-88%below the priceSEK 0.54-53%below the price$71.25

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Cereno Scientific AB Series B: 1 of 1 models see the stock below the current price.

Merck & Company: 24 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Cereno Scientific AB Series B
Bear SEK 0.35Fair Value SEK 0.46Bull SEK 0.69
SEK 4.36 = current price (white tick)
Merck & Company
Bear $70.92Fair Value $125Bull $188
$150 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Cereno Scientific AB Series B · Health Care

Quality score31 · bottom 25%
Fair value upside-89% · bottom 25%

Merck & Company · Health Care

Quality score70 · Top 25%
Fair value upside-17% · above median

Bottom line

As of Sep 5, 2026, Fair Value Calculator sees Merck & Company as the less overvalued of the two: Cereno Scientific AB Series B trades at SEK 4.36 versus a fair value of SEK 0.46 (-89%), while Merck & Company trades at $150 versus $125 (-17%).

Merck & Company has the higher quality score (70/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.